title: Reversible hyporeninemic hypoaldosteronism in a patient with tetraplegia.
abstract: A 66-year-old man with tetraplegia developed hyperkalemia. Hyporeninemic hypoaldosteronism was disclosed on the basis of a lack of response of plasma renin activity to furosemide administration or tilting with marked hypotension and a subnormal response of aldosterone to furosemide stimulation, tilting, angiotensin II infusion and ACTH administration, as well as increased vascular responsiveness to angiotensin II infusion. Of interest was the finding that urinary excretion of epinephrine and norepinephrine was markedly reduced, indicating that hyporeninemia may possibly be due to a chronic lack of sympathetic nervous stimuli. The patient was treated with sodium polystyrene sulfonate resin and/or 9-alpha-fluorohydrocortisone, and wheelchair rehabilitation. However, even after stopping 8-month-mineralcorticoid replacement, normokalemia was maintained. Reexamination of the renin-angiotensin-aldosterone system revealed a normalized response to tilting or ACTH administration along with the normal catecholamine excretion. One more point to be noted is that ACTH administration resulted in a rise in the plasma levels of cortisol, corticosterone and 18-OH-corticosterone, but not aldosterone. This may be attributed to ACTH-stimulated 18-OH-corticosterone derived from the zona fasciculata or alternatively to a partial defect of corticosterone methyl oxidase type II (18-dehydrogenase) in the adrenal glomerulosa cells. These results suggested that hyporeninemic hypoaldosteronism may have been attributable to a decrease in systemic nervous stimuli and that such abnormalities were reversible.
authors.affiliation: Fourth Department of Medicine, Saitama Medical School, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Inaba
authors.forename: S
authors.initials: S
authors.lastname: Katayama
authors.forename: A
authors.initials: A
authors.lastname: Omoto
authors.forename: Y
authors.initials: Y
authors.lastname: Maruno
authors.forename: A
authors.initials: A
authors.lastname: Itabashi
authors.forename: J
authors.initials: J
authors.lastname: Ishii
authors.forename: S
authors.initials: S
authors.lastname: Morimoto
mesh_terms: D000324:Adrenocorticotropic Hormone; D000368:Aged; D000450:Aldosterone / Q000097:blood / Q000652:urine; D000804:Angiotensin II; D001794:Blood Pressure; D004837:Epinephrine / Q000652:urine; D005438:Fludrocortisone / Q000627:therapeutic use; D005665:Furosemide; D006801:Humans; D006994:Hypoaldosteronism / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D008297:Male; D009638:Norepinephrine / Q000652:urine; D011137:Polystyrenes / Q000627:therapeutic use; D011187:Posture; D011782:Quadriplegia / Q000150:complications*; D012083:Renin / Q000097:blood; D012117:Resins, Synthetic
chemical_list: D011137:Polystyrenes; D012117:Resins, Synthetic; D000804:Angiotensin II; D000450:Aldosterone; C003321:polystyrene sulfonic acid; D005665:Furosemide; D000324:Adrenocorticotropic Hormone; D012083:Renin; D005438:Fludrocortisone; D009638:Norepinephrine; D004837:Epinephrine